Immatics N.V. (IMTX) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Replimune Group (REPL) has outperformed Immatics N.V. (IMTX) over the past year, gaining 183.9% versus a loss of 20.8%. Over five years, IMTX leads with a -46.2% price change compared with -56.2% for REPL. Replimune Group is the larger company by market cap ($1.24 billion vs $1.13 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | REPL |
|---|---|---|
| Share price | $7.45 | $13.20 |
| Market cap | $1.13B | $1.24B |
| 1-day change | -0.67% | -0.38% |
| YTD return | -29.05% | +35.80% |
| 1-year return | -20.83% | +183.87% |
| 5-year return | -46.21% | -56.22% |
| EPS (TTM) | $-1.87 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $16.33 |
| 52-week low | $7.31 | $1.50 |
| Distance from 52-week high | -39.97% | -19.17% |
| Average volume | 587.61K | 4.20M |
| Shares outstanding | 152.23M | 94.22M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed IMTX by 204.7 percentage points over the past year.
IMTX vs REPL FAQ
Which is bigger, Immatics N.V. or Replimune Group?
Replimune Group (REPL) is larger, with a market capitalization of $1.24B compared with $1.13B for Immatics N.V. (IMTX).
Which stock has performed better over the past year, IMTX or REPL?
REPL returned +183.87% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.